Mesoblast (MESO) Profit After Tax Growth (3y) (2017 - 2023)

Mesoblast (MESO) Profit After Tax Growth (3y) (2017 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.53%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -27.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 70.25%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Mesoblast 18.89 Bn 18.76 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2023 12.40%
Mar 31, 2023 -6.81%
Dec 31, 2022 0.13%
Sep 30, 2022 -45.79%
Jun 30, 2022 -1.16%
Mar 31, 2022 5.16%
Dec 31, 2021 -1.78%
Sep 30, 2021 -5.31%
Jun 30, 2021 3.51%
Mar 31, 2021 -8.11%
Dec 31, 2020 8.16%
Sep 30, 2020 -24.18%
Jun 30, 2020 -6.30%
Mar 31, 2020 1.50%
Dec 31, 2019 2.23%
Sep 30, 2019 40.48%
Jun 30, 2019 -34.52%
Mar 31, 2019 0.45%
Dec 31, 2018 -3.29%
Sep 30, 2018 -14.00%